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INCIDENCE AND RISK FACTORS ASSOCIATED WITH THE 
DEVELOPMENT OF CYTOMEGALOVIRUS DISEASE AFTER 
INTESTINAL TRANSPLANTATION l 
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From May 1990 to March 1993.38 patients (21 adults 
and 17 children) received 40 allografts that included 
the small bowel (14 isolated small bowel. 21 small 
howel and liver. and 5 multivisceral transplantations). 
Fifteen patients 139%) had 26 episodes of CMV disease: 
7 with one episode, 6 with two, and 1 each with three 
and four. CMV enteritis accounted for 21 (81%) of the 
episodes, hepatitis and pneumonitis for 2 each. and a 
viral syndrome for 1. Cox's proportional hazards uni-
variate and multivariate analyses showed that signif-
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ieant first·episode risk factors were: CMV seropositive 
donors for negative recipients (relative risk (RRJ, 3.86; 
P=O.02), the average daily plasma trough level of ta-
crolimus IRK. 2.15; P=O.04). and total amount of ste-
roid boluses 1 RR., 2.90; P=O.02). CMV disease recur-
rence factors were: CMV seronegative recipients (RR, 
8.60; P=0.02) and total amount of steroid bolus pu.laes 
(RR. 12.39; P=O.004). Because long COUJ'lle8 of l&Dciclo-
vir prophyla.s:is could not prevent the development of 
CMV disease, avoidance of CMV seropositive tn.fta in 
seronegadve recipients and new strategies to prevent 
heavy immunosuppresaion without the penalty of re-
jection will be neceuary to ameliorate this problem in 
intestinal tran.plant recipients. 
Cytomegalovirus is the moat common mfectious complica-
tion after organ transplantation. occumng m S~ to 70,*, of 
kidney, liver. bone marrow. heart. and lung tranSplant reap-
tents \ 1-4). While the prevalence and tumng of CMV infec:-
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tlOn are remarkablY simliar for all the transplanted organs. 
disease entrance IS slgmficantly different In the vanous 
transplant populatIOns (I-·ll. reflecting variable factors in 
pach rather than the selective nrulence of endemic CMV 
,trainS, 
[n the last few \'ears. intestinal transplantation has be-
come a feasible therapeutic option for patients with short 
bowel syndrome. Consequently. we have looked for host fac-
tors 10 our mtestmal transplant recipients who have been 
prone to infection generally 1.5. 6). and who have a particular 
~usceptlbllity to C~ls of the allografts. We present here an 
analYSIS of the inCIdence. timing. clinical outcome. and fac-
tors associated with C:VlV disease in the first 38 intestinal 
transplant recipients at our institution, 
~lA TERlALS AND ~fbqelap 
Patzent popUlation, ,mmunosuppresslL'e treatment. and CMV pro· 
,nhv/n.:ns, From Mav 1990 to March 1993.20 adults and 18 children 
mean dge 20::17 yparsl received 40 intestinal allografts at our 
fn~tgtutilnI Fourteen underwent Isolated small bowel transplanta-
: l()nS, ~ 1 had smail bowel and liver tr:lnsplantatlons. and 5 had 
i\UIUY1,'ceral transplantations. The ~urlncal procedure for each of 
. hl'st' tr:lOsplantatJOns nas been descnbed preVlouslv 17), Immuno· 
-uppre~plve therapy lOciuded tacrohmus lFK5061. ~teroldsK and. in 
, .. leeted cases, low dose AZA (1-2 mglkgldavl, Tacrolimus was gIven 
IIlI1iallv as a contmuous Infusion at a dose of 0,15 mwkglday and 
,'()nvl'rted to an oral dose of 0,3 mwkwday m diVlded doses. 1 to 2 
wt'eks alter transplantatlon. when the patlent became tolerant to 
,'ntera! feedmg, The oral and intravenous routes were overlapped for 
several days at the transition, Trough plasma levels of tacrolimus 
w .. re momtored dad\' With a target therapeutic level between 1 and 
\ n~/mlK In adult patients, methvlpredmsolone was started intraop' 
.'ratl\'t'ly with a I'I! holus followt'd b\' a sterOId taper from :l00 mg to 
~lg ml! o\'t'r ii davs, and maintained at or weaned thereafter from the 
dose of 20 mwda\', ('htldren were gwen 1 ~ of hydrocortIsone Intra· 
"pl'ratl\, .. lv, t'ollowl'd b\' methylpredmsolone, which was tapered over 
" days Irom !OO to Iii mwdav, Prostaglandin 1::1 was started intra-
'llt'f:tt!\'l'l\' at a dose 01 02-0,6 mwkwhr and continued for 7 to 14 
.t,IVS :-'un'Plllance enao~eopy With multlple mucosal blOpsle8 was 
""ftorrnI'O once or tWice per wpek for the lirst J months. and when-
, 'cpr It "';IS (IlmClIl\' Indlcatell therealter, The most severe acute 
:r:lIt n'll'Ctions ""'re treated either by uUI.[1'Tlt!ntlnf,( tacrollmus ther· 
'P\', 1·1! "terold bolus 01 methvlpredmsolone In adults (or hydrocor· 
l"one 11\ children I, a S·dav sterOId burst. or a ii·dav course of OKT3 
mAil yK~ I, Howl'vt'r, not all patients reqUired drastlc treatment. and 
: he rt'soonse to rPl"cllon was commensurate With Its seventy, 
rhlrl.· .. n patients I ,H', I received prophvlaxls With ganclclovir 10 
"H!/kl!'dav lor 2 Wl'l'ks, followed by acyclOVir J200 mwday tadultsl or 
"110 mc'm- ,I times u oav lchddrenl for ti months. In Il patients (:l1':'rl. 
~:meldEFyIlf prophvlaxlS was malntamed for.l months and followed bv 
'Ilch Jnse IIcyclo\'lr untli ti months, £Ieven chddren ana 2 adults who 
,\ pre \ D~ys ,;"ronef,(atlve received onlv C:'IV ·~eronegallve blood prod-
;clS In aodlllOn to their C:.tv·negauve liver, 
I ',\1\' III ,i'CIW" "lin ",liance cuiturn ana definltlon o{ C.UV enter· 
':, :-'p .. clmens I()r \ ~tv cultures and serolollY were obtAmed when-
"'r ,ntectlon was ,-uspected clmlcall\', EI~fs cultures were per· 
','rml'O II\' the ,hell \'lal assav and standard culture techmque. 
"l'roioI!1Cal te~ts lor ED~fs were pert'onned bv a semlautomated 1m-
'!1unollu()rt'scence I FIA.X) test In those patients who were CMV se-
')n .. cutl\'e I n ~ patients. ~ Wlth ana 2 Wlthout c~tv infection. 
l '\\\'·n:-':A W:llI mOnitored tn blood butTv coats ustnl( the polvrnerase 
,num n'3ctJon \ PCR)' !('chmque. 
I~vrnptomatlc C~fs injection wu defined by seroconvenllon or 
, ybb~slatlons: CI. confidence Interval: peR. polymerue ch&1J1 
""actlon: P'TLD. pos~tranaplanD lymphoprohferauve disorder. RR. 
celauve n~kK 
pOSItive culture without evidence of clinical symptoms. Symptomatic 
mfection Included C!\tv viral syndrome and invaSive C~tv disease. 
The diagnOSIS of CMV viral syndrome reqUired laboratory documen-
tation of CMV infection along Wlth fever >3SoC for 2 or more days In 
the absence of other causes. combined Wlth any of the followlnl!' 
findings: atypicallvmphocytosls >3<K. white blood cell count <4,0001 
mmJ • or platelets < 100.000/mmJ , InvaSIve disease was defined as 
tIssue invasion with histopatholOgIC confirmation and/or by isolation 
of virus from a tlssue specImen. CMV ententJs was defined by either 
detection of typical CMV inclusion bodies. unequivocal immunoper' 
oxidase staining of the VlruS. and/or pOSitive culture by either shell 
vial technique or standard culture. along Wlth a mononuclear infil-
trate in intestinal biopsy, Recurrence of CMV disease wa8 defined as 
a new episode of disease after at least 1 month of negative histopa-
thology and/or virology. 
Factors asSOCiated with CMV disease and recurrent diseaM. Thir-
teen clinical variables were analyzed in patients who did and did not 
develop CMV disease: age. type of intestmal transplantation. donor 
and recipient serological status. use of ganClclovir prophyluia. use of 
seronegative blood products, number of units of blood products trans-
fused (packed red cells. plateletA. and fresh frozen pla8mal. treat· 
ment with OKT3. average blood level of tacrollmus per day, average 
daily dose ofmamtenance steroIds (adjusted to weight). AZAIkgtday. 
and the total amount of steroid boluses Inven adjusted to weight . 
Statlstlcal analys",. Univanate and multlvanate analysIs of risk 
factors for the first episode and recurrent c~tv disease were done 
using the Cox proportional hazards model. Pretransplant donor-
recipient serological status wa8 analyzed as Indicator vanabIe USinl!' 
negative donor/negative recIpIent as the reference category. The 
likelihood ratIo chi-square test was used to assess the nsk of each 
factor. Based on the results of these univariate analysis. a multiva· 
nate analysia wa8 performed. Variables were chosen to be included 
m the multivanate analyse8 If they had a P<O,25. The backward 
elimination method was used as a vanable selection technique USing 
the likelihood ratio chi-square test as means to assess each factor, 
Variables were entered or excluded from the model based on a 
P-value for entry of 0.10 and a P-value lor exclusion of 0.15. Approx· 
Imate 95% conlidence intervals (CIl were generated for each relative 
nsk (RR). The cumulative 1·year mortalltv was estimated USing the 
Kaplan-Maler method, 
RESULTS 
Incidence. tlmln~I and treatment of C.\fV di.sease. Fifteen 
patients (39%) developed 26 epIsodes of CMV disease (1.7 
episodes per patient): 7 had 1 episode. 6 had 2. and 1 each 
had 3 and 4, The first episode occurred at a median of 54 days 
I range 21-274). the second at 116 days t range 70-277). the 
third at 173 days ( 159 and 186) and the fourth at 238 days 
after transplantatIOn. CMV ententis was the moat frequent 
type of disease accountmg for 21 EU1~F episodes. There were 
also 2 episodes each of hepatitis and pneumomtis. and 1 of 
vual syndrome. Notably. CMV \1remla was present In only 
10 (48%) of the eplsodes of ententis. despIte apparent clini-
cal. histopathologlc. and/or Vlrologlc SIgnS of infection In the 
mtestmal allograft. Of the 4 patlenta studied WIth PCR. 2 
remamed CMV negative throughout and wtthout any other 
diagnostic cntena of CMV infection. The other 2 developed 
CMV ententia. but In one. Vlremla could not be detected 
contemporaneously WIth peR testing. 
Table 1 shows the donor/recIpient C~ls serolOgIC status. 
mcidence. and number of eplsodes of C~ls disease 10 the 40 
intestma.l transplantauona. None of the 16 seronegative re-
clpienta who receIved seronegauve grafts developed CMV 
disease. Only one of these pauents seroconverted uymptom-
atically 316 daYI after tranapianu.uon_ In contrut. the mCl-
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TABLE l. Donorlrectpient CMV seroiogIcal status and number of 
episodes of C~is disease 
DIR ~oK of DIY disease Episodes transplanta 
16 0 0 
-,1+ 8 o4ERM~F 5 
-/+ 4 2 (50%) 3 
-/- 12 9 (75%) 18 
Total 40" 15 (38%) 26 
" Two patients had two intestmal transplantations. 
dence of CMV disease among C~fs-seropositive recipients 
was 50%. regardless of whether the donor's serologic status 
was negative (418) or positive (214). Two (17%) of these 12 
seropositive recipients had CMV disease recurrence after 
their first postoperative bout of disease. 
Nine (75%) of the high risk group of 12 seronegative recip-
Ients who received seropositive grafts developed 18 episodes 
of CMV disease. Their 9 primary mfections and 9 recurrences 
accounted for 69% of the 26 disease episodes in the study, 
wlth an overwhelming incidence oi intestinal graft involve-
ment. Of the 3 exceptional patients who escaped this compli-
cation. 2 died after 23 and 49 posttransplantation days, and 
the third was diagnosed of asymptomatic infection 103 days 
after transplantation. 
When CMV disease was diagnosed. the first episode was 
treated with ganciclovir 10 mg/kglday for 21 days. The second 
episode was treated with either ganclcloVlr 10 mgtkg/day or 
foscarnet 180 mg/kg/day for 1 month. Recurrence after the 
second episode was treated with either ganclciovir 10 mg/kg/ 
day or foscarnet 180 mgtkglday for 3 months and a mamte-
nance dose of 5 mg/kg/day of ganclciovir or 90-120 mgtkg/day 
of foscarnet thereafter. All dosages of ganclcloVlr and foscar-
net were adjusted for renal function. Four patients developed 
C~ disease recurrence during mamtenance ganclciovir 
therapy and were converted to foscarnet. When 2 of them 
recurred dunng maintenance Foscarnet. inductIOn doses of 
ganclciovlr and C\fV-speClfic hypenmmunglobuhn (100 mw 
kg/weekI were added to the foscarnet therapy, despite which 
1 of the patients developed a new recurrence dunng the tnple 
therapy. This last patient was then gIVen mduction doses of 
ganclcioVlr and foscamet for 3 months. followed by mainte-
nance doses of both antlvirals. No further episodes occurred 
dunng the subsequent 4 months. 
Twenty-sIx (68%) of the 38 patients sUrVlved > 1 year. Of 
the 12 deaths. 7 were among the 15 patients (47%) in whom 
C~ disease developed. occumng 253= 131 days after trans-
plantation. However. evidence of active CM\' disease at 
death and/or autopsy was present 10 only 1 pauent. Five pa-
tients (22%) who did not develop C~fs disease died at 105 = 141 
days alter transplantauon (Fig. 11. Using the Kaplan-Meier 
analvsls. 1-year SUrVlVal did not show a statlSucal difference 
between the two groups (P=O.3). The pnnClpal causes of death 
were techrucal complicatlons (n=3). infectious complicatlons 
In = 5). rejection t n = :2). and d.i.saenunated posttrarulplant Iym. 
phoproliferatlve disorders (PTLDl (n=21. 
CMV L'S. r~g~ctlo" or iymphoprolDf~ratDvl! d~asl!K A mean 
4 episodes of histopathololPc acute allogralt reJecuon oc-
curred per pauent. Beyond the 3 posttransplant months. 73% 
of pauenta who develol*i CMV diaeue expenenced rejection 
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FIGURE 1. One-year patient survival in intestinal transplant recip-
ients m whom CMV disease did and did not develop. 
those patients who did not develop CMV disease. Four pa-
tients (11%) developed PTLD at 243=141 days after trans-
plantation. Two of these patients experienced CMV disease 
before the development of PTLD. 
Factors associated with the first episode and recurrence of 
CMV disease. Variables found with univariate analysis to be 
significantly associated with the development of a first epi-
sode of CMV disease mcluded: donor seropositive/recipient 
seronegative status. isolated small bowel transplantation. 
the average level per day of tacrolimus. the average dose of 
maintenance steroids per day adjusted to patients weight, 
and the amount of pulse steroids adjusted to weight (Table 
2). Multivanate analysis (Table 2) showed that significant 
risk factors for the first episode of C~fs disease were donor 
seropositiVe/recipient seronegative status (RR, 3.86: 95% cr. 
1.21-12.36: P-=O.021. the average level of tacrolimus per day 
IRR. 2.15; 95% CI. l.02-4.52: P=O.041. and the amount of 
sterOlds gwen as pulses (RR. 2.90: 95% CI. 1.16-7.29; 
P=O.021. Factors assOCiated with recurrence ofCMV disease 
were the donor seropositiVe/recipient seronegative status 
I RR. 8.60: 95% cr. 1.46-50.53; P=O.021 and the amount of 
steroids gwen as pulses (RR. 12.39; 95% CI, 1.16-131.83; 
P=O.0041. 
DISCUSSION 
The hazard of CMV infection in recipients of whole organs 
and bone marrow has been noted almost from the beglnmng 
of successful clinical use of these procedures (9). Realization 
that the donor organ IS a frequent inoculation source (JO) as 
well as a vulnerable posttransplantatlon target, and recog-
nition that C~{s disease frequency IS associated Wlth the 
intenSity of immunosuppression are common to all kinds of 
allograit recipients. The InfectiOUS syndromes resemble those 
found in pauents Wlth inherited (J 1) or virus-induced ac-
qWred immune deficiency disorders (121. 
The strong aSSOCiation between the development and/or 
recurrence of C~fs disease and the amount of both tacroli-
mua and steroid pulses was ex~tedK Both drop inhibit 
cell-mediated responsetl. through blockade of cytokine ex. 
presalon \13, 14), impeding the m.am hoa' mechlni,"" agamat 
CMV iruect.lonl (15), Humoral Unmtmlty, which alao ia im· 
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T.-\BLE 2. L'nivanate and multlvanate analysis of risk factors ior the first episode of CMV disease 
L"mvanate ~lugtivanate 
\'anable C~fs disease ~o disease Relative Relative 
nsk 95'1> CI P nsk 95'1> CI P 
K-yge~ 31 <2-50) to (0.5-58) 1.02 0.99-1.06) 0.14 
Seronelrauve blood' 5 (33'.C) 13 (57%) 0.57 10.20-1.68) 0.31 
D'/R-o< 9 (600'cl 3 (13%) 5.89 12.00-17.27) 0.001 3.86 ' 1.21-12.36) 0.02 
Isolated small bowel Txb 9 (SO,}) 5 (22%) 0.33 1MK1O~K94F 0.04 
Ganclciovlr prophyiaJUsb 8 (53'7c) 14 (61%) 0.70 10.25-1.94) 0.49 
FFP' 410-53) 5 (0-100) 1.00 10.98-1.03) 0.95 
PLT' 6(0-196) 8 (0-129) 1.00 10.99-1.01) 0.78 
PRca 23(4-65) 26 (7-128) 0.99 10.97-1.02) 0.46 
qacrolimus~ 2.47 (1.23-4.01) l.67 (0.58-4.36) 3.63 11.95-6.76) 0.0001 2.15 ' 1.02-4.52) 0.04 
SterOid bolusu 0.77 (0.11-2.72) 0.34 (0.08-1.43) 4.45 12.13-9.29) 0.0001 2.90 \ 1.16-7.29) 0.02 
Steroid maintenancea 0.54 (0.16-2.33) 0.31 (0.07-1.82) 2.95 11.16-7.51) 0.02 
AZA,h 8(53%) 12(54%) 0.84 10.30-2.33) 0.73 
OKT3h 0 4 <18%) 
., ~edian and range. 
~ ~umber of patients and percentalre. 
, D'!R -. donor positive/recIpient negative. 
T.-\BLE J. Risk factors associated Wlth recurrent eMV disease 
l'nlvanate 
\'anable 
Relauve nsk 95 .. Cl 
Age L08 11.03-1.14) 
Seronegative blood 0.13 10.02-1.05) 
D '/R-n 15.21 13.09-74.95) 
Isolated small bowel Tx 0.13 EMKOT~KSPF 
Tacrohmus 4.65 11.70-12,68) 
SterOId bolus 18.68 13.55-98.26) 
, D '!R -. donor positiVe/recIpIent negatIve. 
portant in protection from progressive infection of the immu· 
nocompromlsed host (16). is suppressed by high dose sterOId 
therapy, which decreases serum Immunoglobulin levels wIth 
.\ de laved maximal effect 2-4 weeks after treatment (Ii). 
I ;astrOlntestmal lesIOns that contain cytomelralic cells have 
heen reported m assoclatlon WIth sterOId therapy (18, 19), 
prompting several authors to propOHe that sterOld·assoclated 
peptic ulcer disease may be, In iact. a CMV disease (20, 211. 
While the types of CMV infections In our intestinal reclp-
lents have been slmIiar to those receIVIng other organs. the 
,'pldemlOloglc pattern has been distmgulshed by a high inCI-
dence of infection and recurrence rates In the bowel allograft 
I tself. a 50% inCidence of CMV disease m patients who were 
~erlplpltfyDe before transplantation. less than 50% incidence 
1)1' viremIa. and relative mtracubIiitv of the dIsease. Although 
the :.!tj epIsodes of C~is disease In 15 patients did not sIgmf· 
Icantlv deln'ade l·year patient survlYal In companson to 
C~is·rree patients. there was an Increased trend to mortality 
;\S well as very dIfficult management problems. 
The pOSSIbility that the gastromtestInal tract has a partlC' 
ular tropIsm for the Vlrus has been suggested by the 30-50% 
IOcldence otC~is·positive cultures In ostenSIbly normal gas-
troduodenal biopsy of kidney and liver reCIpients (22-24), 
.md In patients With acqUIred Immune deficiency syndrome 
tn wnom the gastrointestinal tract and retma are the most 
common targets of CMV infection 112. 25). Although it haa 
been shown recently that endothelial cells are a common 
target for C~is infectIon (26, 27). gutrotntesunal epIthelial 
cells can also harbor the VlnJa 125. 28) and could be a cause of 
:'Iultlvanate 
P Relative nsit 95'1> Cl P 
0.003 
0.06 
0.0008 8.60 11.46-50.53) 0.02 
0.01 
0.003 
0.0008 12.39 11.16-131.83) 0.004 
relapse. The presence in the intestine of large numbers of 
donor lymphocytes, monocytes. and polymorphonuclear leu· 
kocytes 129) could make the intestine a pnme target for CMV 
Infection because most of these leukocytes presumably con· 
tain latent VlruS (301. Added to this milieu. Ischemic mJury to 
the mucosa dunng preservation and the occurrence of reJec· 
tlon In the vast majonty of cases 18) could make the Intestmal 
graft an Ideal sanctuary for the ViruS. which partIcularly 
infects inflamed or regenerating tissues (31, 32) without nec· 
essarily bemg ret1ected in Vlremla. 
[t was not pOSSible to rule out m these patients that the 
unusual Cl\iV protile herein reported was caused by ganci· 
clovir· or foscarnet·reslstant CMV strams (33), This was due 
to the difficulty in isolating the VlruS when the patients were 
receIving antIviral therapy loU). Althoulth sporadic spot 
checks 10 other kinds of organ reCIpIents failed to demon-
strate antlVlral drug resIstance. this IS something that needs 
to be conSidered. partIcularly in those patients who receIve 
antIVlral therapy for long penods of time. 
[nsight Into the spectacular ability of organs from CMV 
carrier.! to Infect recipients. or. conversely. of an infected 
recipient to infect a graft. haa come from recent discovery of 
the ubiqwtous mIgratIon of donor -passenger" leukocytes 
that beglns Within a few mmutes after graft revaaculariza-
tlon t35-38). The mfectIous potential of these long-sW'Vlving 
chimenc cells is obvious. and presumably related. to the rei-
aUve cell doae sprayed into reclplent tissues from different 
transplanted organa pl"OCUred from carnera of CMV (and 
presumably some other VlruaeSJ. Because a long course of 
1014 TRANSPLANTATION Vol. 59, No.7 
currently available prophylaxis cannot prevent life-threaten-
ing CMV disease In the unusually vulnerable Cl\IV-negative 
Intestmal recIpient. avoidance of Cl\IV-seropositive grafts 
has overriding Importance. Approaches to prevent long-term. 
heavy immunosuppression are a possible future alternatIve. 
One such initiatIve may be to augment the spontaneous cell 
migration by admimstering C~fs-negatlve donor bone mar-
row before surgery. Although this strategy would have been 
considered heretical until recently, it has proved to be safe 
and effective wIth all other organs. including the leukocyte-
rich liver \38L 
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